Evidence map›Paper›PMID 40776485›Full record

Observational studyBJU international2026

Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.

Linda Dey, Juhana Rautiola, Olof Akre, Lars Egevad, Abolfazl Hosseini, Reza Mehrazin, Jaakko Patrakka, Daniel Ranti, Lotta Renström-Koskela, John Sfakianos and 5 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Linda DeyDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0004-0349-3290
Juhana RautiolaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0008-7208-6321
Olof AkreDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Lars EgevadDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8531-222X
Abolfazl HosseiniDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Reza MehrazinDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jaakko PatrakkaDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Daniel RantiDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8310-1063
Lotta Renström-KoskelaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
John SfakianosDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tomas ThielDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8182-3129
Per Henrik VincentDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Jane YanDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Gunnar Steineck *Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Peter WiklundDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Funding

Region Stockholm research grant 2019-1137Signe and Olof Wallenius Stiftelse
6 · The paper itself

Abstract

objectiveTo describe the oncological outcomes for patients with newly diagnosed bladder cancer, as long-term oncological outcomes and natural history of different initial subtypes of diagnoses of bladder cancer are understudied. PATIENTS AND

methodsThis was a prospective, multicentre population-based cohort study, where newly diagnosed patients with bladder cancer from 1995 to 1996 in Stockholm County, Sweden were followed. The primary outcome was cancer-specific mortality (CSM), separately analysed for low-grade non-muscle-invasive bladder cancer (NMIBC Low), high-grade non-muscle-invasive bladder cancer (NMIBC High), and muscle-invasive bladder cancer (MIBC). We used cumulative incidence with competing risk to assess survival outcomes.

resultsIn total, 526 patients were included, 396 had NMIBC. Out of 102 patients with T1, 37% died of bladder cancer during the 25-year follow-up. The rate of CSM for NMBIC Low was 3%, NMIBC High 26%, and MIBC 71%, respectively. For the operated patients with MIBC, the 5-year CSM was 39%. Of the 178 patients with NMIBC High, 22% progressed to MIBC, 10% had lymph node progression, and 17% progressed to metastatic disease during the follow-up. The main limitation of the study is that it was established 30 years ago.

conclusionIn this population-based study, we found that patients with NMIBC High had a persistent risk of CSM up to 25 years from the initial diagnosis, more specifically in patients with T1 tumours. The study demonstrates the importance for optimal treatment for selective high-risk T1 patients with long life expectancy, and high risk of progression.

Indexed as

Urinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesSwedenbladder cancercancer‐specific mortalitylong‐term follow‐upprogressionurothelial cancer

Identifiers

PMID40776485
PMCPMC12690347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.